- Home
- ROIV vs LSCC Comparison
ROIV vs LSCC Comparison
Compare ROIV & LSCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- LSCC
- Stock Information
- Founded
- ROIV 2014
- LSCC 1983
- Country
- ROIV United Kingdom
- LSCC United States
- Employees
- ROIV N/A
- LSCC 1110
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- LSCC Semiconductors
- Sector
- ROIV Health Care
- LSCC Technology
- Exchange
- ROIV Nasdaq
- LSCC Nasdaq
- Market Cap
- ROIV 8.4B
- LSCC 6.8B
- IPO Year
- ROIV N/A
- LSCC 1989
- Fundamental
- Price
- ROIV $10.79
- LSCC $52.53
- Analyst Decision
- ROIV Buy
- LSCC Strong Buy
- Analyst Count
- ROIV 4
- LSCC 13
- Target Price
- ROIV $17.50
- LSCC $65.46
- AVG Volume (30 Days)
- ROIV 5.9M
- LSCC 2.9M
- Earning Date
- ROIV 05-29-2025
- LSCC 05-05-2025
- Dividend Yield
- ROIV N/A
- LSCC N/A
- EPS Growth
- ROIV N/A
- LSCC N/A
- EPS
- ROIV N/A
- LSCC 0.37
- Revenue
- ROIV $122,585,000.00
- LSCC $488,736,000.00
- Revenue This Year
- ROIV N/A
- LSCC $3.50
- Revenue Next Year
- ROIV N/A
- LSCC $18.74
- P/E Ratio
- ROIV N/A
- LSCC $141.99
- Revenue Growth
- ROIV 140.04
- LSCC N/A
- 52 Week Low
- ROIV $8.73
- LSCC $34.69
- 52 Week High
- ROIV $13.06
- LSCC $78.29
- Technical
- Relative Strength Index (RSI)
- ROIV 50.06
- LSCC 54.53
- Support Level
- ROIV $10.58
- LSCC $45.17
- Resistance Level
- ROIV $11.77
- LSCC $57.23
- Average True Range (ATR)
- ROIV 0.34
- LSCC 2.37
- MACD
- ROIV -0.07
- LSCC 0.75
- Stochastic Oscillator
- ROIV 17.65
- LSCC 61.03
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About LSCC Lattice Semiconductor Corporation
Lattice Semiconductor Corp is a developer of semiconductor technology that it distributes through products, solutions, and licenses. The company reaches its customers through consumer, communications, and industrial markets. The company has one operating segment namely the core Lattice business that includes silicon-based and silicon-enabling products, evaluation boards, development hardware, and related intellectual property licensing, services, and sales. The products of the company are offered globally; and, the majority of sales are derived from customers in Asia. It also has its presence in Americas and Europe.